AveXis (NASDAQ:AVXS) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

AVXS has been the topic of a number of other research reports. Evercore ISI initiated coverage on AveXis in a research report on Wednesday, August 16th. They set an “outperform” rating and a $120.00 target price on the stock. Royal Bank Of Canada restated a “hold” rating and set a $92.00 target price on shares of AveXis in a research report on Thursday, November 2nd. Chardan Capital reiterated a “buy” rating and issued a $130.00 price target (up previously from $102.50) on shares of AveXis in a report on Friday, August 11th. BMO Capital Markets reiterated a “buy” rating and issued a $123.00 price target on shares of AveXis in a report on Friday, August 11th. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $134.00 price target (up previously from $89.00) on shares of AveXis in a report on Tuesday, September 5th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $110.67.

AveXis (AVXS) remained flat at $$94.81 on Friday. 263,907 shares of the company’s stock were exchanged, compared to its average volume of 296,786. AveXis has a 52-week low of $44.68 and a 52-week high of $108.27.

AveXis (NASDAQ:AVXS) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.04). During the same period in the prior year, the business earned ($0.87) earnings per share. equities analysts forecast that AveXis will post -6.23 EPS for the current year.

In other news, insider Brian K. Kaspar sold 15,000 shares of AveXis stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.23, for a total value of $1,518,450.00. Following the transaction, the insider now owns 1,841,019 shares in the company, valued at $186,366,353.37. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $97.25, for a total value of $173,105.00. Following the completion of the transaction, the vice president now owns 1,780 shares in the company, valued at approximately $173,105. The disclosure for this sale can be found here. Insiders have sold 33,560 shares of company stock worth $3,393,698 in the last 90 days. Company insiders own 18.60% of the company’s stock.

A number of large investors have recently made changes to their positions in AVXS. California Public Employees Retirement System bought a new stake in AveXis during the 3rd quarter valued at approximately $570,000. Cubist Systematic Strategies LLC boosted its position in shares of AveXis by 688.6% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock worth $175,000 after purchasing an additional 1,577 shares in the last quarter. Highbridge Capital Management LLC bought a new stake in shares of AveXis in the 3rd quarter worth approximately $967,000. Perceptive Advisors LLC boosted its position in shares of AveXis by 147.5% in the 3rd quarter. Perceptive Advisors LLC now owns 671,181 shares of the company’s stock worth $64,923,000 after purchasing an additional 400,000 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in shares of AveXis by 52.2% in the 3rd quarter. Janus Henderson Group PLC now owns 1,027,221 shares of the company’s stock worth $99,363,000 after purchasing an additional 352,456 shares in the last quarter. Institutional investors own 92.88% of the company’s stock.

WARNING: This piece of content was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/03/valuengine-lowers-avexis-avxs-to-sell.html.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.